Anavex Life Sciences Corp. $AVXL inked a material transfer agreement with Biogen $BIIB under which Biogen will test Anavex�s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell (OPC) differentiation assay. A satisfactory outcome from the OPC assay study may lead to an in vivo remyelination study using a chemical demyelination model.